These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21455413)

  • 1. Benign prostatic hyperplasia: An overview of existing treatment.
    Dhingra N; Bhagwat D
    Indian J Pharmacol; 2011 Feb; 43(1):6-12. PubMed ID: 21455413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.
    Miller J; Tarter TH
    Clin Interv Aging; 2009; 4():251-8. PubMed ID: 19554096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the use of dutasteride in the management of benign prostatic hypertrophy.
    Miller J; Tarter TH
    Clin Interv Aging; 2007; 2(1):99-104. PubMed ID: 18044081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
    O'Leary MP
    Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Kim EH; Brockman JA; Andriole GL
    Asian J Urol; 2018 Jan; 5(1):28-32. PubMed ID: 29379733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current role for combination therapy in male LUTS.
    Chung DE; Kaplan SA
    Arch Esp Urol; 2010 Jun; 63(5):323-32. PubMed ID: 20587837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benign prostatic hyperplasia progression and its impact on treatment.
    Djavan B; Waldert M; Ghawidel C; Marberger M
    Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
    Kulig K; Malawska B
    Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination pharmacological therapies for the management of benign prostatic hyperplasia.
    Cohen SA; Parsons JK
    Drugs Aging; 2012 Apr; 29(4):275-84. PubMed ID: 22428659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
    Fonseca J; Martins da Silva C
    Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.
    Sandhu JS; Vaughan ED
    Drugs Aging; 2005; 22(11):901-12. PubMed ID: 16323969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.